Efficacy assessments included 20 % improvement in American College of Rheumatology ( ACR20 ) response , C-reactive-protein-based , 28-joint-count Disease Activity Score ( DAS28-CRP ) response , 75 % improvement in Psoriasis Area and Severity Index ( PASI75 ) scores , and PsA-modified Sharp/van der Heijde scores ( SHSs ) .